BMJ 2002;324:1545 ( 29 June )

Papers

Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence

Francine M Ducharme, associate professor

Departments of Paediatrics and of Epidemiology and Biostatistics, McGill University Health Centre, Montreal, QC H3H 1P3, Canada

Francine.ducharme{at}muhc.mcgill.ca

Objectives: To examine the evidence for the efficacy and glucocorticoid sparing effect of oral anti-leukotrienes taken daily as add-on therapy to inhaled glucocorticoids in patients with asthma.
Design: Systematic review of randomised controlled trials of children and adults with asthma comparing the addition of anti-leukotrienes or placebo to inhaled glucocorticoids.
Main outcome measures: The rate of exacerbations of asthma requiring rescue systemic glucocorticoids when the intervention was compared to the same or double dose of inhaled glucocorticoids, and the glucocorticoid sparing effect when the intervention was aimed at tapering the glucocorticoid.
Results: Of 376 citations, 13 were included: 12 in adult patients and one in children. The addition of licensed doses of anti-leukotrienes to inhaled glucocorticoids resulted in a non-significant reduction in the risk of exacerbations requiring systemic steroids (two trials; relative risk 0.61, 95% confidence interval 0.36 to 1.05). No trials comparing the use of anti-leukotrienes with double the dose of inhaled glucocorticoids could be pooled. The use of anti-leukotrienes resulted in no overall group difference in the lowest achieved dose of inhaled glucocorticoids (three trials; weighted mean difference -44.43 µg/day, -147.87 to 59.02: random effect model) but was associated with a reduction in withdrawals owing to poor asthma control (four trials; relative risk 0.56, 0.35 to 0.89).
Conclusions: The addition of anti-leukotrienes to inhaled glucocorticoids may modestly improve asthma control compared with inhaled glucocorticoids alone but this strategy cannot be recommended as a substitute for increasing the dose of inhaled glucocorticoids. The addition of anti-leukotrienes is possibly associated with superior asthma control after tapering of glucocorticoids, but the glucocorticoids sparing effect cannot be quantified at present.

What is already known on this topic
Anti-leukotrienes are increasingly being used as add-on therapy to inhaled glucocorticoids

No systematic review of randomised controlled trials has examined the evidence to support this treatment strategy

What this study adds
There is a shortage of relevant trials testing anti-leukotrienes at licensed doses as add-on therapy to inhaled glucocorticoids in patients, particularly children





© BMJ 2002

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Anti-leukotrienes do not benefit asthma
BMJ 2002 324: 0. [Full Text]

This article has been cited by other articles:

  • Joos, S, Miksch, A, Szecsenyi, J, Wieseler, B, Grouven, U, Kaiser, T, Schneider, A (2008). Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 63: 453-462 [Abstract] [Full text]  
  • Irvin, C. G., Kaminsky, D. A., Anthonisen, N. R., Castro, M., Hanania, N. A., Holbrook, J. T., Lima, J. J., Wise, R. A. (2007). Montelukast and Theophylline: No Use or Some Use in Persistent Asthma?. Am. J. Respir. Crit. Care Med. 175: 1094a-1095 [Full text]  
  • Becker, A., Lemiere, C., Berube, D., Boulet, L.-P., Ducharme, F. M., FitzGerald, M., Kovesi, T., on behalf of The Asthma Guidelines Working Group o, (2005). Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003. CMAJ 173: S3-S11 [Full text]  
  • (2002). Adding Antileukotrienes to Glucocorticoids Doesn't Add Much for Asthmatics. JWatch General 2002: 5-5 [Full text]  

Rapid Responses:

Read all Rapid Responses

Non-steroidal anti-inflammatory effects of leukotriene receptor antagonists
Graeme P. Currie, et al.
bmj.com, 1 Jul 2002 [Full text]
An editorial step too far?
Richard M Brown
bmj.com, 7 Jul 2002 [Full text]
Anti-leukotriene modifying drugs in chronic persistent bronchial asthma
Dr S K Agarwal
bmj.com, 28 Jul 2002 [Full text]
Side effects of Antileukotrienes
Atef B Michael
bmj.com, 29 Jul 2002 [Full text]
Conclusions on review need caution
Mike Thomas
bmj.com, 29 Jul 2002 [Full text]
The headline might be misleading.
Yuji Oba
bmj.com, 28 Aug 2002 [Full text]
responses to 4 electronic responses
Francine M. Ducharme
bmj.com, 11 Oct 2002 [Full text]
anti-leukotrienes and churg-strauss syndrome
dr.manan vasenwala
bmj.com, 26 Jul 2003 [Full text]



Doc2Doc Vacancy
Access jobs at BMJ Careers
Whats new online at Student 

BMJ